162632-54-4

Upstream product

• 15570-12-4 3-methoxybenzenethiol 
• 100-47-0 benzonitrile 

Downstream Products

• 289038-49-9 2-((2-Benzoyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal 
• 178678-63-2 2-((2-benzyl-5-methoxyphenyl-sulfonyl)methyl)-2-ethylhexanal 
• 289038-48-8 2-(2-benzoyl-5-methoxy-phenylsulfanylmethyl)-2-ethyl-hexanal 

Relevant academic research and scientific papers

Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (part 1)

Elevated plasma levels of low-density lipoprotein (LDL) cholesterol are a major risk factor for atherosclerosis leading to coronary artery disease (CAD), which remains the main cause of mortality in Western society. We believe that by preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug. A series of novel benzothiepines (3R,3R′-2,3,4,5-tetrahydro-5-aryl-1- benzothiepin-4-ol 1,1-dioxides) were synthesized and tested for their ability to inhibit the apical sodium dependent bile acid transport (ASBT)-mediated uptake of [14C] taurocholate (TC) in H14 cells. A 3R,4R,5R/3S,4S,5S racemate was found to have greater potency than the other three possible racemates. Addition of electron-donating groups such as a dimethylamino substituent at the 7 position greatly enhanced potency, and incorporation of a long-chain quaternary ammonium substituent on the 5-phenyl ring was useful in minimizing systemic exposure of this locally active ASBT inhibitor while also increasing water solubility and maintaining potency. The reported results describe the synthesis and SAR development of this benzothiepine class of ASBT inhibitors resulting in an 6000-fold improvement in ASBT inhibition with desired minimal systemic exposure of this locally acting drug candidate.

Hypolipidemic 1,4-benzothiazepine derivative

The invention is concerned with a novel hypolipidemic compound, which is of (3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-5-phenyl-1,4-benzothiazepin-8-ol 1,1-dioxide; or a salt, solvate, or physiologically functional derivative thereof, with processes for its preparation, pharmaceutical compositions containing it and with its use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as athersclerosis.

Hypolipidemic 1,4-benzothiazepine-1,1-dioxides

The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis. STR1

Hypolipidaemic compounds

The invention provides novel 1,4-benzothiazepine compounds substituted with hydroxy or a group containing hydroxy, compositions comprising such compounds and their use in the treatment or prophylaxis of treating clinical conditions in which inhibition of bile acid uptake is indicated, for example, hyperlipidemia and atherosclerosis.

Hypolipidaemic condensed 1,4-thiazepines

The invention provides a compound of formula (I), wherein n is an integer of from 0 to 2; R is an optional substituent; R1 is hydrogen or C1-6 alkyl; R2 is an atom or group selected from hydrogen, C1-4 alkyl (including cycloalkyl and cycloalkylalkyl), C1-4 alkoxy, pyrryl, thienyl, pyridyl, 1,3-benzodioxolo, phenyl and naphthyl, which groups are optionally substituted; R3 is hydrogen, OH, C1-6 alkyl, C1-6 alkoxy or --O C1-6 acyl; R4 is a group independently selected from C1-6 alkyl (including cycloalkyl and cycloalkylalkyl), C2-6 alkenyl, and C2-6 -alkynyl which groups are optionally substituted; R5 is a group independently selected from C2-6 alkyl (including cycloalkyl and cycloalkylalkyl), C2-6 alkenyl and C2-6 alkynyl, which groups are optionally substituted; or R4 and R5, together with the carbon atom to which they are attached, form a C3-7 spiro cycloalkyl group which is optionally substituted; R6 and R7 are independently selected from hydrogen and C1-6 alkyl; and X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein optionally one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur, or X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur; and salts, solvates and physiologically functional derivatives thereof, pharmaceutical formulations comprising such compounds, processes for their preparation and their use in reducing bile acid uptake and hence as hypolipidaemic compounds. STR1